Article info

Download PDFPDF

PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

Authors

  • Joseph Vento Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of Internal MedicineUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Aditi Mulgaonkar Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of RadiologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Layton Woolford Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Division of Hematology/Oncology, Department of Internal MedicineUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Kien Nham Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of RadiologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Alana Christie Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of Clinical SciencesUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Aditya Bagrodia Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of UrologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Alberto Diaz de Leon Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of RadiologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Raquibul Hannan Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of Radiation OncologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Isaac Bowman Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Division of Hematology/Oncology, Department of Internal MedicineUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Renee M. McKay Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Division of Hematology/Oncology, Department of Internal MedicineUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Payal Kapur Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of PathologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Guiyang Hao Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of RadiologyUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • Xiankai Sun Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Department of RadiologyUniversity of Texas Southwestern Medical Center Dallas TX USA Advanced Imaging Research CenterUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  • James Brugarolas Kidney Cancer Program, Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical Center Dallas TX USA Division of Hematology/Oncology, Department of Internal MedicineUniversity of Texas Southwestern Medical Center Dallas TX USA PubMed articlesGoogle scholar articles
  1. a joseph.vento{at}phhs.org
  2. b aditi.mulgaonkar{at}utsouthwestern.edu
  3. c layton.woolford{at}utsouthwestern.edu
  4. d kien.nham{at}utsouthwestern.edu
  5. e alana.christie{at}utsouthwestern.edu
  6. f aditya.bagrodia{at}utsouthwestern.edu
  7. g alberto.diazdeleon{at}utsouthwestern.edu
  8. h raquibul.hannan{at}utsouthwestern.edu
  9. i isaac.bowman{at}utsouthwestern.edu
  10. j renee.mckay{at}utsouthwestern.edu
  11. k payal.kapur{at}utsouthwestern.edu
  12. l guiyang.hao{at}utsouthwestern.edu
  13. m xiankai.sun{at}utsouthwestern.edu
  14. n james.brugarolas{at}utsouthwestern.edu
View Full Text

Citation

Vento J, Mulgaonkar A, Woolford L, et al
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

Publication history

  • Received February 8, 2019
  • Accepted May 2, 2019
  • First published June 3, 2019.
Online issue publication 
June 03, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.